<DOC>
	<DOCNO>NCT02870790</DOCNO>
	<brief_summary>A new NSW Ministry Health HIV Strategy release 1 December 2015 aim virtual elimination HIV transmission NSW 2020 . Critical new strategy 's success population-based , targeted roll-out HIV PrEP . PrEP involve take one pill daily co-formulated tenofovir disoproxil fumarate ( TDF ) / emtricitabine ( FTC ) . This large-scale study aim rapid roll-out TDF/FTC individual high risk HIV , comprise mostly gay bisexual men ( GBM ) also include small number heterosexual , inject drug user , transgender men woman . The drug use accord exist NSW Ministry Health Guidelines . By rapidly roll new intervention 12 month period , follow participant two year treatment , reduction 50 % new HIV diagnose NSW expect . The study aim assess incidence HIV among PrEP study participant measure population-level impact rapid roll-out PrEP HIV diagnose among GBM NSW two-year period . It also evaluate rate PrEP uptake among high risk GBM NSW , assess incidence STI ( gonorrhoea , chlamydia infectious syphilis ) among people prescribe PrEP measure effect rapid roll-out PrEP overall number notification gonorrhoea , chlamydia infectious syphilis NSW , describe pattern PrEP use medication adherence , monitor behavioural risk practice among PrEP user . The main population group 3700 gay men high risk HIV infection . All procedure study guide NSW Guidelines PrEP . Protocol Co-Chairs Professor David Cooper , Professor Andrew Grulich . Protocol Coordinating Investigator : Dr. Iryna Zablotska .</brief_summary>
	<brief_title>Expanded PrEP Implementation Communities NSW</brief_title>
	<detailed_description />
	<criteria>HIV negative enrolment , negative HIV test result document within seven day initiate PrEP At high ongoing risk acquire HIV infection sexual exposure ( defined Behavioural Eligibility criterion present Appendix II online Risk Assessment Questionnaire Appendix III ) , OR previously PrELUDE study participant Aged 18 year Live NSW visit NSW enough attend clinic followup assessment Willing able provide inform consent Medicare ineligible individual may enrol clinical service able cover cost monitor patient HIV1 infect symptom consistent acute viral infection ( If HIV positive status confirm testing , delay start PrEP least one month reconfirm negative HIV1 status ) . Having estimate creatinine clearance ( glomerular filtration rate [ GFR ] ) &lt; 60ml/min Having develop clinical symptom suggestive lactic acidosis pronounce hepatotoxicity ( include nausea , vomit , unusual unexpected stomach discomfort , weakness ) Concurrently take nephrotoxic agent ( e.g. , highdose nonsteroidal antiinflammatory drug / NSAIDs ) Allergic TDF and/or FTC ( base selfreport record ) Concurrently take prescribe product contain FTC TDF include ATRIPLA® , COMPLERA® , EMTRIVA , STRIBILD® , VIREAD ; drug contain lamivudine ; HEPSERA Factors condition may compromise participant 's access health service followup ( incarceration plan relocation potential absence NSW duration study ) . Behavioural eligibility criterion per NSW PrEP guideline .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>